Lanreotide injection is used to treat patients who have acromegaly and who have not responded to surgery or radiation. Lanreotide injection is also used to treat patients who have neuroendocrine tumours of the GI tract or pancreas (GEP-NETs) that have spread or cannot be removed surgically. Lanreotide injection belongs to the somatostatin agonist family of drugs. It works by lowering the number of specific hormones that the body produces.
According to the American Association of Neurological Surgeons, Cushing’s disease affects around 10-15 million people each year. Furthermore, the condition primarily affects people aged 20 to 50 years old, with females having a higher prevalence than males. Furthermore, according to NCBI in 2018, the global prevalence of acromegaly is around 4,600 per million people. Acromegaly is also seen in about 116.9 new cases per million per year across the world. Thus the rising incidences of such rare diseases act as a driver for the global Lanreotide market.
Another important driver to the overall market growth is the availability of attractive government insurance plans and programmes for people with rare illnesses. For instance, several government healthcare institutions in the US and Europe, like the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS), provide subsidised medications for rare disorders.
Furthermore, in June 2019, the US Food and Drug Administration (FDA) authorised a new pre-filled syringe for Somatuline Depot (lanreotide) of Ipsen Biopharmaceuticals, a subsidiary of Ipsen. The syringe has been modified with new features such as bigger flanges to make injection administration easier for healthcare practitioners.
To Request a Sample of our Report on Lanreotide Market: https://www.omrglobal.com/request-sample/lanreotide-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Outlook
- By Application
Regions Covered
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Ipsen Pharmaceuticals, Bachem AG, AmbioPharm, ChemWerth Inc., Techland Corporation,
Lanreotide Market by Segments
By Type
- 60mg
- 90mg
- 120mg
By Outlook
- Neuroendocrine Tumors
- Acromegaly
By Application
- Hospital
- Pharmacy
A full Report of Lanreotide Market is Available: https://www.omrglobal.com/industry-reports/lanreotide-market
Lanreotide Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/lanreotide-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
